InsidersTradesSigma

Understanding Insider Buying Before FDA Decisions, Sigma Journal

The Implications of Insider Buying Before FDA PDUFA Dates

How much weight should investors place on insider buying before FDA decisions? This practice can signal confidence but also involves various complexities.

By Sigma Research·May 17, 2026·13 min · 2,771 words

Insiders do not need a crystal ball before an FDA decision, only a calendar and a tolerance for paperwork.

Key takeaways

Biotech insider buying ahead of PDUFA dates is real, but it is lumpy, case-specific, and often concentrated in small-cap companies with financing risk.
A purchase made weeks before an FDA catalyst can signal confidence, but it can also reflect board optics, support for a capital raise, or simple valuation views rather than privileged knowledge.
The legal backdrop is awkward rather than mysterious: US insiders may trade if not in possession of material nonpublic information, yet clinical and regulatory processes create unusually high odds that someone knows something important.
For investors, the useful question is not whether insiders bought before approval, but who bought, how much, under what trading plan, and whether the company had enough cash to survive a delay or rejection.

Biotech has a habit of making ordinary corporate disclosures look theatrical. A Form 4 filed on a Thursday afternoon can read like a confidence vote, a distress flare, or both, especially when the company in question is waiting for an FDA decision that could double the equity or remove the need for future annual reports entirely.

The specific pattern here is insider buying in the weeks before a PDUFA date, the FDA's target action date under the Prescription Drug User Fee Act. The setup is irresistible to markets. There is a binary catalyst, a finite timeline, and a small circle of people who know the asset better than anyone else. Add a stock chart that already resembles a seismograph and you have the ingredients for a very old argument: are insiders telling us something, or merely telling us they would like us to think they are?

That question deserves a sober answer, because biotech is one of the few sectors where insider purchases can plausibly carry more information than in the average industrial company, and also one of the few sectors where the legal and practical constraints on trading are especially severe. The result is not a clean signal. It is a messy one, but a useful messy one.

Act on this

SignalsToday's recommendations ScreenerInsider-signal screener UniverseAll covered companies

Why pre-approval insider buying gets so much attention

A PDUFA date compresses uncertainty into one line on the calendar

Most industries produce information continuously. Biotech often stores it up and releases it in chunks, trial readouts, advisory committee votes, complete response letters, approvals. A PDUFA date is not a guarantee of a decision on that exact day, but it is close enough for trading psychology. It creates a visible countdown to a potentially company-defining event.

That matters because insider transactions are interpreted through context. A chief executive buying shares in a diversified software company may indicate broad confidence in the business. A chief executive buying shares in a single-asset biotech six weeks before an FDA action date is interpreted far more aggressively. The market assumes the buyer has a refined view of manufacturing readiness, labeling risk, post-marketing commitments, or the tenor of late-cycle interactions with the agency.

Sometimes that assumption is too strong. The FDA process is structured, but not fully transparent even to sponsors. Senior management may be optimistic for legitimate reasons and still be wrong. Manufacturing and chemistry, manufacturing, and controls issues have ruined many elegant efficacy narratives. The FDA is not obliged to respect a management team's emotional investment.

The information content of buys is usually higher than the information content of sales

This is a standard insider-trading observation, and it applies with extra force in biotech. Sales are noisy. Executives sell to diversify, pay taxes, fund mortgages, settle divorces, or because their compensation committee has thoughtfully ensured they are rich on paper and cash-poor in practice. Buys are cleaner. They require someone to part with cash, voluntarily, in the open market, at a time when everyone knows a major catalyst is approaching.

The literature has long found that insider purchases tend to be more informative than insider sales, though the effect varies by firm size, information asymmetry, and market regime. Biotech scores highly on all three. Small firms, sparse analyst coverage, and assets whose value depends on technical details that most investors would rather not read after dinner. In such settings, a genuine open-market purchase by a knowledgeable insider deserves attention.

But attention is not the same as automatic bullishness. One recurring mistake is to treat all insider buying as equivalent. It is not. A $50,000 purchase by a newly appointed director in a $2 billion company is not the same as a $2 million purchase by a founder-CEO whose wealth is already tied to the asset. Nor is a purchase under a pre-arranged Rule 10b5-1 plan the same as a discretionary open-market buy made after a long trading blackout expires.

The legal problem is simple to state and hard to police

Insiders are allowed to trade, until they are not

US law does not prohibit insiders from buying or selling their own company's shares merely because they are insiders. It prohibits trading while in possession of material nonpublic information, and it imposes prompt disclosure obligations on directors, officers, and beneficial owners above the relevant threshold. That distinction sounds tidy in textbooks and far less tidy in a development-stage biotech.

Consider the weeks before a PDUFA date. Who knows what? Management may know the content of recent FDA information requests, the status of manufacturing remediation, the likely timing of labeling discussions, and the confidence level of internal regulatory staff. Some of that may be material. Some may be ambiguous. Some may be stale by the time a trade is executed. Companies therefore tend to impose blackout windows around major events, and boards tend to be conservative, at least when counsel is awake.

This is one reason pre-PDUFA insider buying is less common than the folklore suggests. The setup is so sensitive that many companies simply do not permit discretionary trading close to the event. When buys do occur, they can be especially notable precisely because they have already passed through internal compliance filters.

Rule 10b5-1 plans help, but they do not solve the signalling puzzle

A trade under a Rule 10b5-1 plan may reduce legal risk by establishing that the plan was adopted when the insider was not aware of material nonpublic information. Yet from a signalling perspective, such trades are weaker. They may have been scheduled months earlier and tell investors little about current confidence. Recent SEC amendments increased disclosure around 10b5-1 plans and added cooling-off periods for directors and officers, which should improve context but not eliminate ambiguity.

In practice, investors need to read the footnotes. Was the purchase discretionary? Was it under a plan? Was it a one-off or part of a sequence? Did multiple insiders buy around the same time? Did the company also raise capital shortly before or after? The answers matter more than the headline.

Case studies, what the market thinks it sees, and what may actually be happening

Sarepta and the rare-disease template

Rare-disease biotech offers the cleanest examples of pre-catalyst insider conviction because the commercial opportunity can be concentrated and the patient population tightly defined. Sarepta Therapeutics, over multiple regulatory chapters in Duchenne muscular dystrophy, became a reference case for how closely investors watch management behaviour around FDA milestones. Even where no dramatic cluster of insider purchases occurred immediately before a decision, the market treated any insider transaction, financing move, or public statement as part of the approval mosaic.

The lesson from Sarepta is less "insiders bought before approval" than "the market desperately wants insider trades to simplify a complicated regulatory story". That is understandable and usually wrong. Regulatory outcomes in neuromuscular disease have depended on efficacy interpretation, surrogate endpoints, external political pressure, and post-marketing commitments. Insider buying could only ever be one input.

Arena, Intercept, and the obesity or liver disease version of the same drama

In larger catalyst-driven names such as Arena Pharmaceuticals in earlier obesity-drug cycles, or Intercept Pharmaceuticals around liver disease milestones, investors repeatedly searched Form 4s for signs that management confidence was hardening ahead of the FDA. Sometimes there were purchases. Sometimes there were not. Sometimes the stock rallied on the mere absence of selling, which is not a sentence one encounters often outside biotech.

These cases illustrate a useful asymmetry. Ahead of a binary event, insiders may refrain from trading because blackouts are strict or because counsel has sensibly advised against creating a spectacle. Therefore, the absence of buying is not necessarily bearish. Conversely, the presence of buying can be meaningful, but only if it is clearly discretionary and economically non-trivial.

Small-cap oncology and one-asset biotech, where the signal can be strongest and the risk highest

The most striking pre-PDUFA purchases often appear in small-cap oncology or rare-disease companies with one lead asset and limited cash runway. Here, insider buying can mean at least three different things.

First, genuine conviction that the benefit-risk profile will satisfy the FDA.

Second, confidence that even a delay or label restriction leaves the company undervalued.

Third, a desire to stabilise market sentiment before financing discussions.

Those motives are not mutually exclusive. Indeed, they often arrive as a package. A board member may sincerely believe approval odds are favourable and also recognise that a visible purchase helps support the stock into a critical period. Markets prefer one clean motive. Corporate reality rarely cooperates.

How to read a pre-PDUFA buy without embarrassing yourself

Start with the role of the buyer

Not all insiders sit equally close to the relevant information. A chief regulatory officer, founder-CEO, or executive chair with deep scientific involvement may carry more informational weight than an independent director who joined six months ago. That does not mean the director's purchase is irrelevant. It means the interpretation should be proportionate.

There is also a behavioural point. Founder-managers often buy because they are temperamentally inclined to average down and defend the story. Independent directors may buy because they want to signal alignment. A chief financial officer may buy because the balance sheet risk is overdone and not because the FDA outcome is nearly certain. The same transaction code can encode very different motives.

Then look at size, relative size, and clustering

Absolute dollar size matters less than size relative to compensation and existing ownership. A $100,000 purchase by a cash-compensated director may be meaningful. The same amount by a billionaire founder is a rounding error with legal documentation.

Clustering is often more informative than any single trade. If several insiders buy within a short period, especially across management and the board, the signal strengthens. Shared purchases can still be orchestrated, of course, but orchestration itself tells you something. At minimum, the company wants the market to notice. In biotech, companies do not usually invite extra scrutiny near an FDA event unless they believe the optics are worth it.

Check cash, debt, and the next financing need

This is where many investors stop too early. A company with six months of cash and a looming PDUFA date may see insider buying that reflects confidence in survival rather than confidence in an uncomplicated approval. If management believes that even a delayed approval will unlock financing on acceptable terms, they may buy because the equity is cheap relative to long-run value. That can still be a good trade. It is just not the same thesis as "they know approval is coming".

A practical rule helps. If the company would need to raise capital quickly after a negative or delayed decision, insider buying carries a financing overlay. If the company is well funded through launch, the buy is more likely to reflect a purer view on the regulatory and commercial setup.

The comparative angle, why biotech differs from other sectors and jurisdictions

Pharma and biotech have unusually dense information asymmetry

Insider buying in banks is often read through credit cycles. In industrials, through order books and margins. In biotech, the asymmetry is more technical and more episodic. The market may know the trial met its endpoint, but not how the FDA is likely to view subgroup consistency, manufacturing comparability, or inspection findings. This creates a wider gulf between what insiders suspect and what outsiders can reasonably infer.

That does not mean insiders possess a secret approval memo. It means they operate with a richer mosaic. In legal terms, the difference between a mosaic and material nonpublic information is where careers become billable.

Disclosure rules are fast in the US, but not uniquely so

The SEC's two-business-day Form 4 deadline means the market usually sees insider trades quickly. Europe has similar prompt disclosure concepts under MAR for persons discharging managerial responsibilities, though the surrounding market customs differ and biotech catalyst trading is less culturally theatrical than in the US small-cap ecosystem.

Market	Regulator	Rule	Deadline	Notes
US	SEC	Exchange Act Section 16(a) / Form 4	T+2 business days	Directors, officers, and 10% holders disclose reportable changes in beneficial ownership promptly.
FR	AMF	MAR Art 19	T+3 business days	PDMR transactions must be notified by the person and issuer, subject to threshold rules and closed periods.
EU	ESMA and national regulators	MAR Art 19	T+3 business days	Closed periods ahead of annual and interim reports are standard, with limited exceptions.

Insider transaction disclosure is fast on both sides of the Atlantic, but the US biotech market tends to react more dramatically to individual filings.

The practical consequence is that US biotech investors have built a habit of treating insider filings as near-real-time sentiment indicators. Sometimes that is sensible. Sometimes it is merely a way to outsource due diligence to people who are not allowed to tell you what they know.

What the evidence says, and what it does not

Academic evidence supports insider buys as a broad signal, not a biotech oracle

The academic literature generally finds abnormal returns following insider purchases, particularly in smaller firms and in periods of high information asymmetry. That is the good news. The less exciting news is that these are average effects across samples, not a promise that every pre-event biotech purchase predicts a positive FDA outcome.

Biotech is also vulnerable to selection bias in storytelling. Investors remember the dramatic wins, the insider who bought before an approval and looked clairvoyant. They forget the quieter cases where insiders bought, the FDA delayed or rejected, and the stock spent the next year introducing shareholders to the concept of dilution. A proper sample would compare all meaningful pre-PDUFA insider buys against a control set of similar companies without buys, adjusted for size, cash runway, indication, and prior volatility. That is the sort of exercise that improves understanding and ruins cocktail-party anecdotes.

The strongest practical inference is often about expected value, not certainty

This is the most useful framing. A meaningful insider purchase ahead of a PDUFA date does not necessarily say, "approval is likely". It may say, "the insider believes the market is underestimating expected value across approval, delay, and rejection scenarios". That is subtler and more realistic.

For example, if management believes the downside after a complete response letter is cushioned by cash, partnership optionality, or a fixable manufacturing issue, buying before the event can still make sense. Investors who read every pre-PDUFA purchase as a pure approval bet are simplifying a multi-branch decision tree into a coin toss. Markets love a coin toss because it fits in a headline. Biology and regulation remain less cooperative.

A framework for investors tracking these trades now

Build a checklist, not a myth

A sensible framework for evaluating pre-FDA insider buying in biotech would include:

Transaction type: discretionary open-market purchase versus plan-based or indirect transaction.
Buyer identity: operational insider, scientific founder, finance executive, or independent director.
Economic weight: meaningful relative to salary and prior holdings.
Clustering: one buyer or several.
Timing: how close to the PDUFA date, and whether the company was likely in a blackout for part of that period.
Cash runway: enough to survive a negative outcome without immediate financing.
Regulatory context: clean review versus known manufacturing, inspection, or safety issues.
Valuation context: is the stock already pricing high approval odds.
Footnotes: 10b5-1 plan disclosures, indirect ownership, family trusts, and other details that make the difference between signal and paperwork.

This checklist is less thrilling than a tale of insiders loading up before a green light from the FDA. It is also more likely to preserve capital.

The best case studies are the ones with enough detail to disappoint romantics

When this pattern works well as a signal, the setup usually looks plain rather than cinematic. A small or mid-cap biotech with one major near-term catalyst, a manageable cash position, no obvious unresolved manufacturing overhang, and one or more senior insiders making economically meaningful open-market purchases after a long period of inactivity. The market notices. The stock often firms. If approval follows, the filing is later treated as prophecy.

Prophecy is usually just a board-approved trade ticket plus a lot of retrospective storytelling. Still, if one must choose between the stories told by investor-relations decks and the stories told by executives spending their own money, the latter tends to be the less decorative source.

The open question is empirical and worth testing properly: do pre-PDUFA insider buys outperform generic insider buys in biotech after controlling for firm size, cash runway, and prior drawdown? Our dataset for this article did not include live query output, so the honest value for any house statistic is n/a. That leaves a concrete next step. Build the sample, separate discretionary buys from plan trades, tag FDA catalyst dates, and see whether the folklore survives contact with a full distribution rather than three famous anecdotes.